Oruka Therapeutics (ORKA) Competitors $27.91 +0.43 (+1.56%) Closing price 04:00 PM EasternExtended Trading$28.22 +0.32 (+1.13%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORKA vs. MIRM, LNTH, ADMA, ACAD, ZLAB, AAPG, QURE, TLX, CGON, and APLSShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), Ascentage Pharma Group International (AAPG), uniQure (QURE), Telix Pharmaceuticals (TLX), CG Oncology (CGON), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Its Competitors Mirum Pharmaceuticals Lantheus ADMA Biologics ACADIA Pharmaceuticals Zai Lab Ascentage Pharma Group International uniQure Telix Pharmaceuticals CG Oncology Apellis Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk and volatility, MIRM or ORKA? Mirum Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Do insiders and institutionals hold more shares of MIRM or ORKA? 56.4% of Oruka Therapeutics shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 24.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is MIRM or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -13.65%. Mirum Pharmaceuticals' return on equity of -24.76% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-13.65% -24.76% -8.50% Oruka Therapeutics N/A -26.26%-24.16% Do analysts rate MIRM or ORKA? Mirum Pharmaceuticals currently has a consensus target price of $76.50, suggesting a potential upside of 0.41%. Oruka Therapeutics has a consensus target price of $41.80, suggesting a potential upside of 49.77%. Given Oruka Therapeutics' higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Oruka Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media prefer MIRM or ORKA? In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 9 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.82 beat Oruka Therapeutics' score of 0.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, MIRM or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M11.36-$87.94M-$1.21-62.97Oruka TherapeuticsN/AN/A-$83.72M-$2.81-9.93 SummaryMirum Pharmaceuticals beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$2.96B$6.11B$10.46BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-9.9322.7985.3627.36Price / SalesN/A756.67607.16135.99Price / CashN/A172.6337.4661.86Price / Book2.575.5112.426.81Net Income-$83.72M$33.06M$3.32B$276.80M7 Day Performance23.44%0.95%1.01%0.27%1 Month Performance82.90%14.25%10.75%8.31%1 Year Performance0.32%0.85%76.20%35.60% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics3.0317 of 5 stars$27.91+1.6%$41.80+49.8%-0.9%$1.03BN/A-9.93N/AAnalyst ForecastMIRMMirum Pharmaceuticals2.8814 of 5 stars$72.90-1.2%$76.50+4.9%+84.3%$3.67B$429.16M-60.32140Positive NewsLNTHLantheus4.562 of 5 stars$53.38+1.9%$74.50+39.6%-50.3%$3.64B$1.53B14.24700Trending NewsAnalyst RevisionADMAADMA Biologics3.6335 of 5 stars$14.48-1.8%$27.67+91.1%-8.7%$3.46B$426.45M16.88530News CoveragePositive NewsACADACADIA Pharmaceuticals4.5141 of 5 stars$20.16-2.3%$29.12+44.4%+35.8%$3.41B$1.02B15.20510Analyst ForecastZLABZai Lab2.7646 of 5 stars$30.39-7.1%$56.35+85.4%+18.9%$3.40B$398.99M-14.921,869News CoverageAAPGAscentage Pharma Group InternationalN/A$36.40-1.6%N/AN/A$3.39B$134.35M0.00600News CoverageGap UpQUREuniQure3.173 of 5 stars$61.63-3.2%$71.75+16.4%+945.4%$3.37B$27.12M-15.65500TLXTelix Pharmaceuticals4.1867 of 5 stars$9.68-4.1%$21.00+116.9%N/A$3.28B$516.72M0.00N/ATrending NewsAnalyst RevisionGap UpCGONCG Oncology2.1752 of 5 stars$42.79-3.8%$58.82+37.5%+14.2%$3.24B$1.14M-23.9861Gap UpAPLSApellis Pharmaceuticals4.0934 of 5 stars$25.21-2.0%$33.29+32.0%-15.4%$3.18B$754.65M-13.86770News CoverageAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies MIRM Competitors LNTH Competitors ADMA Competitors ACAD Competitors ZLAB Competitors AAPG Competitors QURE Competitors TLX Competitors CGON Competitors APLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
